Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Turke

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2010
PIKing the right patientAlexa B Turke, Jeffrey A Engelman
Cancer Research|May 4, 2012
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptorsAlexa B Turke, Youngchul Song, Carlotta Costa, et al.
Elife|February 17, 2015
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathwaysS Michael Rothenberg, Kyle Concannon, Sarah Cullen, et al.
Cancer Research|July 22, 2011
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancerXuemei Yang, Alexa B Turke, Jie Qi, et al.
Scientific Reports|February 4, 2016
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2Susanne B Breitkopf, Xuemei Yang, Michael J Begley, et al.
Cancer Discovery|March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibRyan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Cancer Cell|February 5, 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLCAlexa B Turke, Kreshnik Zejnullahu, Yi-Long Wu, et al.
Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2010
PIKing the right patientAlexa B Turke, Jeffrey A Engelman
Cancer Research|May 4, 2012
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptorsAlexa B Turke, Youngchul Song, Carlotta Costa, et al.
Elife|February 17, 2015
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathwaysS Michael Rothenberg, Kyle Concannon, Sarah Cullen, et al.
Cancer Research|July 22, 2011
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancerXuemei Yang, Alexa B Turke, Jie Qi, et al.
Scientific Reports|February 4, 2016
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2Susanne B Breitkopf, Xuemei Yang, Michael J Begley, et al.
Cancer Discovery|March 27, 2012
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibRyan B Corcoran, Hiromichi Ebi, Alexa B Turke, et al.
Cancer Cell|February 5, 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLCAlexa B Turke, Kreshnik Zejnullahu, Yi-Long Wu, et al.
Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
Pageof 1